Anixa’s Phase 1/2 breast cancer vaccine trial is enrolling 60 patients across two dose cohorts, with interim safety and immunogenicity readouts slated for mid-2026. The study’s primary endpoint is to evaluate antigen-specific T-cell responses and confirm tolerability, with secondary measures assessing preliminary clinical activity in early-stage patients.

The company’s ovarian cancer CAR-T program has achieved key preclinical milestones, supporting a planned IND submission in Q4 2026. Manufacturing scale-up for autologous CAR-T cells is underway at a partner facility, targeting GMP compliance and readiness for a first-in-human Phase 1 trial.

The CEO identifies 2026 as a pivotal year to de-risk both oncology programs and attract strategic partners or collaborators. To support clinical development, Anixa is evaluating options for a potential financing round and alliance discussions that could provide capital and resources for late-stage activities.